Polypeptide With Localisation/Targeting Motif TRIZ Cases

Protease-cleavable linkers mask CAR-T receptors to prevent on-target off-tumor toxicities while enabling specific tumor targeting.

Chloroplast targeting with a RuBisCO transit peptide boosts PCV2 capsid expression, while polyhistidine tags enable single-step purification.

Selective kinase inhibitors like BTK blockers enhance CAR-T cell proliferation and cytotoxicity while maintaining functionality.

Optimized heavy chain variable regions resolve the trade-off between binding affinity and structural complexity for PSMA-targeted therapies.

A multipartite peptide blocks exosome release from cancer cells by binding to mortalin proteins.

Engineered tumor-infiltrating lymphocytes express membrane-bound interleukin 15 to expand without exogenous cytokines.

Vesicles loaded with CD24 molecules deliver immunomodulators directly to cells, reducing hyper-inflammation and preventing multisystem organ failure.

Recombinant Listeria strains deliver HMW-MAA fragments to elicit a targeted immune response against tumor-associated pericytes.

Self-assembling peptide nanoparticles eliminate in vitro manufacturing complexity while enabling robust CD8+ T-cell immune responses.

Segmented chimeric hemagglutinin expression eliminates co-production bottlenecks, enabling rapid scalable vaccine manufacturing.

Immunogenic composition comprising consensus TERT antigens stimulates robust T cell responses against tumor cells.

Segmented CAR and TCR platforms resolve specificity trade-offs by targeting CD105+ tumors without broad-spectrum limitations.

A ribonucleoprotein complex comprising Cas endonuclease and guide RNA enables precise nucleotide modifications in plant cells.

Specific amino acid modifications in variant PD-1 polypeptides increase binding affinity to PD-L1 while preserving protein structure stability.

Modifying signal sequence parameters reduces broth viscosity and basal expression for easier purification.

Genetically modified mice express humanized CD4 and CD8 co-receptors to mimic human immune responses.

Dominant negative DR5 expression blocks TRAIL-mediated apoptosis in modified T cells, enabling persistence within the hostile tumor microenvironment.

Co-expressing FOXP3 with HLA-specific CARs in regulatory T cells prevents effector phenotype acquisition and reduces transplant rejection risk.

Peptide sequences enable endosomal escape and high transfection rates while avoiding the safety risks of viral vectors.

Engineered bacteriophages deliver antigen genes into commensal bacteria to express protective proteins without causing cell lysis.

Segmented bispecific antibodies targeting CLDN 18.2 reduce off-target toxicity in solid tumors.

Segmented chimeric antigen receptors overcome drug resistance by activating T cells against CD70-expressing cancer cells.

Fusion proteins combine cell recognition and RNA binding to resolve complexity trade-offs, enabling efficient mRNA delivery with reduced structural overhead.

Transgenic microalgae express exogenous antigens for oral vaccine delivery.

A pharmaceutical composition comprising a YEKLLDTEI peptide, histidine buffer, and trehalose filler.

Engineered antigen binding units with distinct CDR sequences form scFv structures for targeted cancer cell destruction.

Engineering CAR T cells with Boolean logic gates reduces off-target toxicity by requiring specific antigen combinations for activation.

Tamoxifen-induced nuclear transport of ERT2-Cas9 resolves complexity and time bottlenecks in animal model DNA editing.

Engineered Cas9 systems recognize alternate protospacer adjacent motifs to expand genome coverage density.

Secreted cathepsin K and MMP7 degrade dense tumor stroma, resolving the contradiction between infiltration ability and anti-tumor efficacy.

Separate mRNA delivery of a cytidine deaminase, nickase, and uracil glycosylase inhibitor controls enzyme ratios to minimize bystander mutations.

UMG1 antibodies resolve UN1 hybridoma availability issues by replicating binding specificity while enabling precise targeting of lymphocyte subsets.

A cytokine-based multi-epitope protein binds to CCR7-positive cells to stimulate innate and adaptive immune responses.

Segmented peptide antagonists inhibit GEF-H1 function, resolving specificity trade-offs in treating inflammatory diseases.

Fusion proteins merge CRISPR-Cas effectors with deaminases to resolve low base pair conversion efficiency in genetic editing systems.

Segmented CAR-T administration reduces cytokine release syndrome risk while maintaining therapeutic effectiveness through optimized timing.

Staged production processes with increased medium volume to surface area ratios reduce production time and labor costs for adoptive cell therapy.

Dual-expression plasmids enable Bifidobacterium to secrete multiple antibodies locally, reducing systemic side effects while enhancing anticancer efficacy.

Peptides penetrate cells and nuclei to inhibit oncogene expression by disrupting YAP-TEAD interactions.

Engineered cells expressing multiple chimeric antigen receptors prevent immune escape by targeting diverse tumor antigens simultaneously.

A switch molecule mediates binding between effector cells and target cells to enable controlled activation states.

A non-ApoH signal peptide directs recombinant ApoH export from cells to increase protein yield.

Self-associating tetramerization domains assemble effector proteins into specific multimers, resolving purity and yield trade-offs in manufacturing.

Tetraspanin fusion proteins replace large extracellular loops with heterologous sequences to stabilize peptide presentation and prevent cytosolic degradation.

Segmented signaling domains require combined tumor ligand and hypoxia inputs to trigger T cell activation, reducing off-target effects on healthy tissue.

A chimeric peptide delivers neuroprotective agents into cells via an internalization sequence.

J domain fusion proteins bridge Hsp70 and target proteins, resolving therapy effectiveness versus specificity trade-offs in proteopathies.